Premium InsightsThe Hepatitis C drug market is entering a transformative phase as global health organizations, pharmaceutical ...

Younger age, substance use, and HCC may be risk factors for repeat HCV viremia in patients who achieve SVR following DAA therapy.

Atea’s Phase 3 trial evaluating the regimen of bemnifosbuvir and ruzasvir for the treatment of adults with chronic hepatitis C virus (HCV). C-BEYOND is an open-label trial being conducted in the ...

SHELTON, CT / ACCESS Newswire / April 14, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the "Company"), and a leading global pioneer in the development of broad-spectrum ...

From a public health point of view, there are no specific strategies for prevention of hepatitis E virus infection. Exposures ...

Hepatitis C virus (HCV) and nonalcoholic fatty liver disease (NAFLD) are the two most common causes of chronic liver disease in North America. NAFLD represents a spectrum of liver lesions that ...

Source: Therapy Watch HCV data – Research Partnership In ... a 65% reduction in associated mortality. Worldwide, the hepatitis C virus infects an estimated 130-150 million people chronically ...

Enanta Pharmaceuticals, Inc.’s ENTA share price has surged by 7.51%, which has investors questioning if this is right time to ...

Expanded DAA access led to reduced HCV-related hospitalization rates in patients with HIV, but HCV admissions remain higher in those with vs without HIV.

Less than three years after Sovaldi’s launch, hepatitis C (hep ... make HCV screening more routine is getting underway. Gilead says 14 million people in the US were screened for the virus ...

The U.S. capacity to battle hepatitis B and C has been leveled a devastating blow with the recent closure of the CDC’s ...

Uncover what drives alcoholic hepatitis, how it’s detected, and why stopping alcohol is vital for better health and recovery.